Mitral stenosis and hypertrophic obstructive cardiomyopathy: An unusual combination

Joonhwa Hong, MD, PhD,^a Hartzell V. Schaff, MD,^a Steve R. Ommen, MD,^b Martin D. Abel, MD,^c Joseph A. Dearani, MD,^a and Rick A. Nishimura, MD^b

ABSTRACT

Objective: Systolic anterior motion of mitral valve (MV) leaflets is a main pathophysiologic feature of left ventricular outflow tract (LVOT) obstruction in hypertrophic obstructive cardiomyopathy. Thus, restricted leaflet motion that occurs with MV stenosis might be expected to minimize outflow tract obstruction related to systolic anterior motion.

Methods: From January 1993 through February 2015, we performed MV replacement and septal myectomy in 12 patients with mitral stenosis and hypertrophic obstructive cardiomyopathy at Mayo Clinic Hospital in Rochester, Minn. Preoperative data, echocardiographic images, operative records, and postoperative outcomes were reviewed.

Results: Mean (standard deviation) age was 70 (7.6) years. Preoperative mean (standard deviation) maximal LVOT pressure gradient was 75.0 (35.0) mm Hg; MV gradient was 13.7 (2.8) mm Hg. From echocardiographic images, 4 mechanisms of outflow tract obstruction were identified: systolic anterior motion without severe limitation in MV leaflet excursion, severe limitation in MV leaflet mobility with systolic anterior motion at the tip of the MV anterior leaflet, septal encroachment toward the LVOT, and MV displacement toward the LVOT by calcification. Mitral valve replacement and extended septal myectomy relieved outflow gradients in all patients, with no death or serious morbidity.

Conclusions: Patients with mitral stenosis and hypertrophic obstructive cardiomyopathy have multiple LVOT obstruction mechanisms, and MV replacement may not be adequate treatment. We favor septal myectomy and MV replacement in this complex subset of hypertrophic obstructive cardiomyopathy. (*J Thorac Cardiovasc Surg* 2016;151:1044-8)

Displacement of the MV toward the LVOT by calcification. (Used with permission of Mayo Foundation for Medical Education and Research.)

Central Message

Mitral valve stenosis can co-occur with obstructive hypertrophic cardiomyopathy and is best managed with myectomy and mitral valve replacement.

Perspective

Systolic anterior motion of the mitral valve has a central role in obstructive physiology of hypertrophic cardiomyopathy. However, we have encountered patients who have both obstructive hypertrophic cardiomyopathy and limited mobility of mitral leaflets due to mitral valve stenosis. Multiple mechanisms can lead to obstruction, and optimal treatment is septal myectomy and mitral valve replacement.

See Editorial Commentary page 1049.

See Editorial page 906.

Left ventricular outflow tract (LVOT) obstruction in hypertrophic cardiomyopathy is related to systolic anterior motion of the mitral valve (MV) leaflets in contact with the subaortic septum.^{1,2} In patients who have hypertrophic cardiomyopathy and MV stenosis, the valve leaflets usually have limited mobility, which might be expected to minimize systolic anterior motion and dynamic LVOT

obstruction. Some studies have reported isolated cases of the combination of MV stenosis and hypertrophic obstructive cardiomyopathy,³⁻⁸ but none have identified or proposed mechanisms of LVOT obstruction.

The aim of the present study was to evaluate the pathophysiologic characteristics and surgical outcome of patients who underwent MV replacement and septal myectomy for mitral stenosis and hypertrophic obstructive cardiomyopathy at our institution.

METHODS

Patients

From January 1993 through February 2015, a total of 12 patients with the preoperative diagnosis of MV stenosis and obstructive hypertrophic cardiomyopathy underwent MV replacement and septal myectomy at Mayo Clinic Hospital in Rochester, Minn. During that interval, a total of 2162 adults (age ≥ 18 years) had an operation for hypertrophic

From the Divisions of ^aCardiovascular Surgery, ^bCardiovascular Diseases, and ^cCardiovascular and Thoracic Anesthesia, Mayo Clinic, Rochester, Minn.

J.H. is now with the Department of Thoracic and Cardiovascular Surgery, Heart Research Institute, Chung-Ang University College of Medicine, Seoul, Korea.

Received for publication Aug 10, 2015; revisions received Nov 12, 2015; accepted for publication Nov 27, 2015; available ahead of print Dec 24, 2015.

Address for reprints: Hartzell V. Schaff, MD, Division of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (E-mail: schaff@mayo.edu). 0022-5223/\$36.00

Copyright © 2016 by The American Association for Thoracic Surgery

<http://dx.doi.org/10.1016/j.jtcvs.2015.11.048>

Abbreviations and Acronyms

LVOT = left ventricular outflow tract
MV = mitral valve

cardiomyopathy. The study protocol was approved by the Mayo Clinic Institutional Review Board. Preoperative data, operative records, and postoperative outcomes in the electronic health records and our prospective surgical database were reviewed. Detailed analysis of preoperative transthoracic and intraoperative transesophageal echocardiographic images was performed to characterize the anatomic relationship between the MV and the subaortic septum, to identify possible mechanisms of outflow tract obstruction.

RESULTS

Preoperative Characteristics

Mean (standard deviation) age was 70 (7.6) years; 11 patients were women. Mean (standard deviation) New York Heart Association functional class was 3 (0.6); 10 patients (83%) were in New York Heart Association functional class III or IV. On preoperative echocardiography, the mean (standard deviation) was 75.0 (35.0) mm Hg (range: 29-125 mm Hg) for maximal LVOT pressure gradient, and for MV gradient, 13.7 (2.8) mm Hg (Table 1).

Pathophysiologic Mechanisms of LVOT Obstruction

Four main mechanisms of LVOT obstruction were identified in the patients with mitral stenosis and hypertrophic obstructive cardiomyopathy (Figure 1). Eleven of our 12 patients had combinations of pathophysiologic mechanisms of LVOT obstruction (Table 2). The first mechanism observed was systolic anterior motion of MV leaflets without severe limitation in leaflet motion. In patients with this mechanism, MV leaflet motion was not severely limited, even with significant MV stenosis; thus, the mechanism of LVOT was similar to that in hypertrophic obstructive cardiomyopathy without mitral stenosis.

The second mechanism identified was systolic anterior motion at the tip of the MV leaflet, with severe limitation in MV motion. With this mechanism, only the body of the MV was calcified with limited motion, leaving the tip mobile, and the tip of the MV leaflet moved toward the LVOT, causing systolic anterior motion and LVOT obstruction. The third mechanism was focal septal hypertrophy encroaching on the LVOT. With this mechanism, septal hypertrophy is prominent at the base of the septum, forming a fixed obstruction of the LVOT. With the fourth mechanism, marked calcification and displacement of the anterior leaflet of the MV toward the LVOT resulted in LVOT obstruction. A separate level of obstruction was present in the midventricle in 3 patients.

Operations and Outcomes

All 12 patients underwent MV replacement (6 mechanical valves and 6 bioprostheses) and septal myectomy. Mean

(standard deviation) aortic crossclamp time and cardiopulmonary bypass time were 89.8 (30.7) minutes and 107.7 (32.1) minutes, respectively. In 11 patients, LVOT pressure gradients were relieved completely after the surgery; the sole patient with residual gradient had concomitant aortic valve replacement with a 21-mm aortic bioprosthesis in 1999. No operative deaths occurred, and the median length of hospital stay was 8 days (range: 5-27 days; Table 1).

DISCUSSION

The relationship between MV regurgitation and obstructive hypertrophic cardiomyopathy is well known, and experience has shown that in most patients, systolic anterior motion of the MV and related MV regurgitation resolve after successful septal myectomy^{9,10} (JH Hong, HV Schaff, RA Nishimura, MD Abel, JA Dearani, Z Li, and SR Ommen, unpublished data, 2015). However, little is known about the mechanisms of outflow tract obstruction in patients who have hypertrophic cardiomyopathy and restricted motion of the MV leaflets.

Systolic anterior motion of the MV leaflets is caused by complex anatomic and physiologic interactions between the left ventricular outflow and the MV apparatus that produce systolic anterior motion of the MV.^{11,12} However, none of the previous explanations of systolic anterior motion has accounted for the possible mechanism of LVOT obstruction in patients who have mitral stenosis and hypertrophic cardiomyopathy.

In the present review, we found that mechanisms of the LVOT obstruction in patients with mitral stenosis and hypertrophic cardiomyopathy were multiple and complex. In our case patients, the various pathophysiologic mechanisms included: systolic anterior motion with or without severe limitation of the MV leaflets; septal encroachment toward the LVOT; and distortion of the base of the MV toward the LVOT with calcification. Thus, although systolic anterior motion producing outflow tract obstruction may occur in patients who have restrictive MV disease, the latter 2 mechanisms explain how LVOT obstruction can occur without systolic anterior motion.

In addition to these mechanisms, a separate level of obstruction at midventricle may cause symptoms.¹³ Categorizing 4 mechanisms of LVOT obstruction on the basis of echocardiography data of a limited number of patients may be an oversimplification, and more mechanisms of LVOT obstruction could be present in other patient groups. But, even if other mechanisms are present that might not be found in our patient groups, we assume that they are few and are concurrent with the 4 mechanisms we found.

Concomitant MV surgery is recommended at the time of myectomy for patients who are known to have significant MV stenosis,¹⁴ because relief of outflow tract obstruction alone would not be expected to correct symptoms related

TABLE 1. Perioperative data of the 12 patients

Patient no.	Age (y)	Gender	NYHA class	Preoperative echocardiogram value			CPB time, min	ACC time, min	Valve	Postop LVOT gradient, mm Hg	Length of stay, d
				LVOT gradient, mm Hg	MV gradient, mm Hg	HR, beats/min					
1	78	F	3	ND	20	73	119	74	Mech	ND	27
2	76	F	4	43	16	76	147	130	Bio	36*	13
3	74	F	4	93	12	64	129	115	Mech	No	6
4	76	F	2	125	12	96	63	50	Bio	No	8
5	75	F	3	29	17	96	46	37	Bio	No	8
6	81	F	3	61	18	113	81	65	Bio	5	9
7	58	M	3	96	5	74	135	106	Mech	No	9
8	66	F	2	64	12	62	101	94	Bio	No	6
9	71	F	3	81	14	96	145	135	Bio	No	5
10	58	F	3	83	10	60	116	106	Mech	No	8
11	68	F	3	81	13	110	119	93	Mech	No	6
12	64	F	3	70	15	83	91	73	Mech	No	26

NYHA, New York Heart Association; LVOT, left ventricular outflow tract; MV, mitral valve; HR, heart rate; CPB, cardiopulmonary bypass; ACC, aortic crossclamp; *postop*, postoperative; F, female; ND, no data available; *mech*, mechanical prosthesis; *bio*, bioprosthesis; M, male. *LVOT pressure gradient from the patient who underwent concomitant aortic valve replacement with 21-mm bio.

to pathologic valve characteristics. But outflow tract obstruction in patients with known symptomatic MV stenosis might be missed if the surgeon does not recognize that the two can coexist. In such cases, MV replacement alone may not correct outflow tract obstruction when the cause is not related to systolic anterior motion of the leaflets; we believe that in such cases, concomitant septal myectomy should be performed. In this situation, the septal myectomy may not need to be as extensive as one performed as an isolated procedure. When MV replacement is performed without myectomy in a patient with both diseases, careful intraoperative investigation with transesophageal Doppler echocardiography and direct pressure measurement¹⁵ is

critically important to make certain no residual obstruction is present after isolated MV replacement.

The choice of MV prostheses depends on the usual patient-related factors, including age and need for systemic anticoagulation. Patients who have septal hypertrophy may have a theoretical advantage by having a low-profile mechanical prosthesis rather than a bioprosthesis to replace the MV. However, in our series, in which all patients had concomitant myectomy, bioprostheses were used in 50% of the patients, with no complications related to residual gradients.

Although transatrial myectomy has been proposed by some surgeons,^{16,17} transaortic exposure is our preferred

FIGURE 1. Schematic images of pathophysiologic mechanism of LVOT obstruction. A, Systolic anterior motion without severe limitation in MV motion. B, Severe limitation in MV motion with systolic anterior motion at tip of the MV. C, Septal encroachment toward the LVOT. D, Displacement of the MV toward the LVOT by calcification. AV, Aortic valve; LV, left ventricle; LVOT, left ventricular outflow tract; MV, mitral valve; LA, left atrium; RVOT, right ventricular outflow tract. (Used with permission of Mayo Foundation for Medical Education and Research.)

TABLE 2. Pathophysiologic mechanisms of obstruction

Patient no.	Limitation in MV mobility	Obstruction mechanism*			
		SAM	Septal encroachment	Leaflet distortion toward LVOT	Midventricular obstruction
1	+++	—	+	++	+
2	++	—	++	—	—
3	++	+	+	—	—
4	+++	—	+	+++	—
5	++	—	—	+	++
6	++	+	++	—	—
7	++	++	+++	+	—
8	+	+	+	+	—
9	+	++	+	+	—
10	+	++	+	—	—
11	+	+	+	++	++
12	++	—	+	++	—

MV, Mitral valve; SAM, systolic anterior motion; LVOT, left ventricular outflow tract. *Scores ranged from — to +++. —, absent; +++, severe.

approach for isolated septal myectomy,^{18,19} because transaortic septal myectomy can be performed without such direct MV procedures as detachment of the MV anterior leaflet. In cases of combined MV replacement and septal myectomy, in which septal exposure for myectomy might be adequate after excision of the diseased MV, transatrial myectomy may be a reasonable approach, depending on surgeon preference and familiarity with the procedure.

The number of our 12 patients for whom rheumatic valvular disease was the cause of their valve stenosis is impossible to determine. Patients in this study were older in general than myectomy patients at our institution,²⁰ and than patients in previous case reports.³⁻⁸ In view of the more-advanced patient age in our study, and the relatively low prevalence of rheumatic valvular disease in North America, degenerative, age-related calcific MV disease is the likely cause of mitral stenosis in many of our patients. Even though the patients who underwent MV replacement and septal myectomy in our study were relatively older, the operative results were satisfactory, and the postoperative LVOT pressure gradients were relieved successfully after the operation in all patients.

CONCLUSIONS

In the rare combination of MV stenosis and hypertrophic obstructive cardiomyopathy, multiple mechanisms affect LVOT obstruction, which might not be relieved completely with isolated MV replacement. To achieve complete symptomatic relief, the surgeon should target the operation to treat multiple pathophysiologic mechanisms, and appropriate myectomy and MV surgery should be considered.

Conflict of Interest Statement

Authors have nothing to disclose with regard to commercial support.

References

1. Henry WL, Clark CE, Griffith JM, Epstein SE. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). *Am J Cardiol.* 1975; 35:337-45.
2. Maron BJ, Harding AM, Spirito P, Roberts WC, Waller BF. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. *Circulation.* 1983;68:282-93.
3. Nathan MJ, DeSanctis RW, Buckley MJ, Sanders CA, Austen WG. Idiopathic hypertrophic subaortic stenosis and mitral stenosis. *Ann Thorac Surg.* 1971;12: 191-5.
4. Nanda NC, Gramiak R, Shah PM, Stewart S, DeWeese JA. Echocardiography in the diagnosis of idiopathic hypertrophic subaortic stenosis co-existing with aortic valve disease. *Circulation.* 1974;50:752-7.
5. Gash AK, Ferri DP, Kolff J, Carabello BA, Spann JF. Coexistent mitral stenosis and dynamic left ventricular outflow obstruction. *Cathet Cardiovasc Diagn.* 1983;9:381-90.
6. Goswami KC, Reddy KS, Shrivastava S. Rheumatic mitral stenosis associated with hypertrophic cardiomyopathy and anomalous muscle bundle in the right ventricle. *Int J Cardiol.* 1993;38:189-92.
7. Neema PK, Varma PK, Sinha PK, Rathod RC, Mahmood F, Park KW, et al. Case 4-2006: coexistent hypertrophic obstructive cardiomyopathy, mitral stenosis, and coronary artery fistula. *J Cardiothorac Vasc Anesth.* 2006;20:594-605.
8. Sharma J, Tewari S, Kapoor A. Unusual coexistent rheumatic mitral stenosis and hypertrophic cardiomyopathy. *Asian Cardiovasc Thorac Ann.* October 3, 2014 [Epub ahead of print].
9. Nakatani S, Schwammenthal E, Lever HM, Levine RA, Lytle BW, Thomas JD. New insights into the reduction of mitral valve systolic anterior motion after ventricular septal myectomy in hypertrophic obstructive cardiomyopathy. *Am Heart J.* 1996;131:294-300.
10. Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. *J Am Coll Cardiol.* 2000;36:2219-25.
11. Nakatani S, Marwick TH, Lever HM, Thomas JD. Resting echocardiographic features of latent left ventricular outflow obstruction in hypertrophic cardiomyopathy. *Am J Cardiol.* 1996;78:662-7.
12. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. *Circulation.* 1993;87:1570-9.
13. Falicov RE, Karunaratne HB, Cahill N, Lamberti JJ Jr. Hypertrophic cardiomyopathy with midventricular obstruction associated with mitral stenosis: partial relief of the obstruction by papillary muscle and trabecular resection. *Cathet Cardiovasc Diagn.* 1977;3:247-58.
14. Wan CK, Dearani JA, Sundt TM III, Ommen SR, Schaff HV. What is the best surgical treatment for obstructive hypertrophic cardiomyopathy and degenerative mitral regurgitation? *Ann Thorac Surg.* 2009;88:727-31.
15. Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura RA, Abel MD. Intraoperative direct measurement of left ventricular outflow tract gradients to

guide surgical myectomy for hypertrophic cardiomyopathy. *J Thorac Cardiovasc Surg.* 2011;142:53-9.

16. Gutermann H, Pettinari M, Van Kerrebroeck C, Vander Laenen M, Engelen K, Fret T, et al. Myectomy and mitral repair through the left atrium in hypertrophic obstructive cardiomyopathy: the preferred approach for contemporary surgical candidates? *J Thorac Cardiovasc Surg.* 2014;147:1833-6.
17. Lillehei CW, Levy MJ. Transatrial exposure for correction of subaortic stenosis. *JAMA.* 1963;186:8-13.
18. Schaff HV, Said SM. Transaortic extended septal myectomy for hypertrophic cardiomyopathy. *Oper Tech Thorac Cardiovasc Surg.* 2012;17:238-50.

19. Said SM, Schaff HV. Surgical treatment of hypertrophic cardiomyopathy. *Semin Thorac Cardiovasc Surg.* 2013;25:300-9.

20. Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: results of operation in patients with latent obstruction. *J Thorac Cardiovasc Surg.* 2012;143:303-9.

Key Words: hypertrophic cardiomyopathy, mitral stenosis, mitral valve replacement, myectomy

Readers who found these articles interesting may also like to read the following papers found in recent and future issues of our sister publications, *Seminars in Thoracic and Cardiovascular Surgery* and *Operative Techniques in Thoracic and Cardiovascular Surgery*!

Acquired: Valvular Heart Disease

Original Submission: Posterior Leaflet Detachment, Augmentation, and Reconstruction for Treatment of Functional Mitral Valve Regurgitation. Rakesh M. Suri. *Semin Thorac Cardiovasc Surg* 2015; Summer; 27(2):91-94.

Editorial Commentary: Patch Augmentation of Mitral Valve Leaflet in Ischemic Mitral Regurgitation. Tirone E. David. *Semin Thorac Cardiovasc Surg* 2015; Summer; 27(2):95-96.

Original Submission: Elevated Stroke Risk Associated with Femoral Artery Cannulation During Mitral Valve Surgery. Kareem Bedeir. *Semin Thorac Cardiovasc Surg* 2015; Summer; 27(2):97-103.

Editorial Commentary: Are We Going Backwards or Forwards in Minimally Invasive Mitral Valve Surgery? Three Eras of Perfusion Strategy. Vinay Badhwar. *Semin Thorac Cardiovasc Surg* 2015; Summer; 27(2):104-105.

Current Readings: Selection of Valve Prostheses. Cristian Rosu. *Semin Thorac Cardiovasc Surg* 2015; Summer; 27(2):152.

State of the Art: Strategies and Devices to Minimize Stroke in Adult Cardiac Surgery. Richard M. Engelman. *Semin Thorac Cardiovasc Surg* 2015; Spring; 27(1):24-29.

State of the Art: Minimally Invasive Valve Surgery: When Less is More. Joseph Lamelas. *Semin Thorac Cardiovasc Surg* 2015; Spring; 27(1):49-56.

Discussion in Cardiothoracic Treatment and Care: Surgical Ablation for Atrial Fibrillation. Marc Gillinov. *Semin Thorac Cardiovasc Surg* 2015; Spring; 27(1): 65-79.

Original Submission: Hemodynamic performance of the aortic valve late after David I: An echocardiographic study. Antonino Rubino. Expected Publication December 2015.

Editorial Commentary: Back to David I. Tirone David. *Semin Thorac Cardiovasc Surg* 2015; Autumn; 27(3):264-265.

Discussion in Cardiothoracic Treatment and Care: Aortic Valve/Root Repair. Tirone David. *Semin Thorac Cardiovasc Surg* 2015; Autumn; 27(3):271-287.

Biatrial Transseptal Approach for Combined Mitral Valve and Tricuspid Valve Operations. Mahim Malik. *Oper Tech Thorac Cardiovasc Surg* 2015; Spring; 20(1):2-16.

Mitral Valve Replacement for Infective Endocarditis with Annular Abscess: Annular Reconstruction. Gregory J. Bittle. *Oper Tech Thorac Cardiovasc Surg* 2015; Spring; 20(1):17-30.

Reoperative Aortic Valve Replacement After Previous Coronary Artery Bypass Grafting or Aortic Valve Replacement. Marc R. Moon. *Oper Tech Thorac Cardiovasc Surg* 2014; Winter; 19(4):482-499.

Mitral Annuloplasty Using A Biodegradable Annuloplasty Ring. Sanjay Cherian. Expected publication April 2016.